文献速递脑血管病神经重症与神经感染

BEST-MSU研究中移动卒中单元黄金一小时内的tPA治疗

Golden Hour Treatment With tPA (Tissue-Type Plasminogen Activator) in the BEST-MSU Study.
PubMed 文献 · Stroke · 2023-01-23

在BEST-MSU试验中分析941例接受静脉tPA治疗的急性缺血性卒中患者,206例(21.8%)在60分钟内开始溶栓。与较晚治疗相比,首小时治疗与90天改良Rankin量表评分0-1分的调整比值比升高相关(OR 1.87,95%CI 1.25-2.84,P=0.003),且不增加出血风险,并降低治疗神经血管模仿病的风险。

要点

  • 941例接受tPA治疗的患者中,206例(21.8%)在60分钟内开始溶栓治疗。
  • 首小时治疗与90天改良Rankin量表评分0-1分的调整OR为1.87(95%CI 1.25-2.84,P=0.003)。
  • 首小时治疗不增加出血风险,并与降低治疗神经血管模仿病的风险相关。

核心结论

  • 与较晚治疗相比,首小时治疗几乎使优秀临床结局的 odds 翻倍,且不增加风险,支持使用移动卒中单元。

研究设计与样本

  • BEST-MSU研究为移动卒中单元与标准急救医疗服务救护车管理的交替周整群对照试验,本文分析其中所有接受静脉tPA治疗的患者。

主要发现

  • 941例接受tPA治疗的患者中,206例(21.8%)在60分钟内开始溶栓治疗。
  • 移动卒中单元治疗、年龄较大、男性、经911报警、更快的到达现场和影像检查、更严重的卒中、心房颤动、无心力衰竭及无预先降压治疗与首小时治疗相关。
  • 与较晚治疗相比,首小时治疗与90天改良Rankin量表评分0-1分的调整比值比升高相关(OR 1.87,95%CI 1.25-2.84,P=0.003)。
  • 首小时治疗患者中,68%达到90天改良Rankin量表评分0或1分或恢复至基线状态。
  • 首小时治疗与出血风险升高无关,并与降低治疗神经血管模仿病的风险相关。

临床怎么用

  • 作者结论认为首小时治疗几乎使优秀临床结局的 odds 翻倍且不增加风险,支持使用移动卒中单元。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of patients with acute ischemic stroke on mobile stroke units (MSUs) improves outcomes compared with management by standard emergency medical services ambulances and is associated with more patients treated with intravenous tPA (tissue-type plasminogen activator) in the first golden hour after last known normal. We explored the predictors and outcomes of first-hour treatment (FHT) compared with later treatment in an alternating-week cluster-controlled trial of MSUs. METHODS: We analyzed all patients treated with intravenous tPA in the BEST-MSU Study (Benefits of Stroke Treatment Delivered by a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services). After stratifying by treatment timeframe, we identified factors associated with FHT. We performed adjusted analyses of the association between FHT and clinical outcome and modeled the shape of the relationship between last known normal-to-treatment time and excellent outcome. RESULTS: Among 941 tPA-treated patients, 206 (21.8%) had lytic started within 60 minutes. Treatment on the MSU, older age, male sex, alert by 911, faster arrival on-scene and imaging, more severe stroke, atrial fibrillation, and absence of heart failure and pretreatment antihypertensive treatment were associated with FHT. Compared with later treatment, FHT was associated with higher adjusted odds ratio for 90-day modified Rankin Scale score of 0 to 1 (odds ratio, 1.87 [95% CI, 1.25-2.84]; P=0.003). Among FHT patients, 68% achieved a 90-day modified Rankin Scale of 0 or 1 or returned to their baseline status. FHT was not associated with higher risk of hemorrhage and was associated with reduced risk of treating neurovascular mimics. CONCLUSIONS: FHT almost doubles the odds of excellent clinical outcome without increased risk compared with later treatment, which supports the use of MSUs.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mackey J, Yamal JM, Parker SA, et al. Golden Hour Treatment With tPA (Tissue-Type Plasminogen Activator) in the BEST-MSU Study. Stroke. 2023. PMID: 36689579. doi:10.1161/STROKEAHA.122.039821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。